Renewal denial after stable disease: documenting continued benefit

A patient with metastatic non-small cell lung cancer has been on pembrolizumab for eight months. Scans show stable disease—no progression, no new lesions, but also no measurable shrinkage. The oncology practice submits a prior authorization renewal. The payer denies it: "Documentation does not demonstrate continued clinical benefit."

This scenario is common across oncology, immunology, and rare disease. Payers grant initial prior authorization based on diagnosis, biomarker status, and treatment history. But at renewal—typically every 3 to 12 months—they require evidence that the drug is still working. When the patient is stable but not improving, the documentation often fails to satisfy the payer's criteria.

This article explains why stable disease triggers renewal denials, what documentation access teams need for each therapeutic area, and how to build a reauthorization workflow that prevents treatment gaps. It is written for manufacturer hub teams, field reimbursement specialists, provider-office access coordinators, and specialty pharmacy staff who manage prior authorization renewals for chronic specialty therapies.

Why stable disease triggers renewal denials

The "response vs. stability" mismatch

Many payer clinical policies for specialty drug reauthorization require evidence of "clinical benefit," "positive clinical response," or "disease improvement." The language comes from the clinical trial endpoints used to support the drug's approval: response rates, remission rates, or improvement on standardized disease activity scores.

But in practice, many patients achieve stability rather than improvement. In oncology, stable disease is a recognized RECIST outcome and is clinically meaningful—preventing progression is the therapeutic goal for many advanced cancers. In immunology, a patient with rheumatoid arthritis who maintains low disease activity (rather than remission) is still deriving benefit. In rare disease, stabilization may be the best achievable outcome.

The mismatch occurs when payer policy language requires "improvement" but the clinical reality is "no worsening." Alexion's reauthorization guide for specialty medications notes that "health plans often require a reauthorization after a specified time period to confirm that the drug continues to be medically necessary and that the patient has responded to therapy."

How payers phrase the renewal requirement

Common reauthorization criteria language from 2026 payer policies:

The Geisinger language—"continued disease improvement or lack of disease progression"—is the most clinically appropriate because it explicitly recognizes stability as a valid outcome. But many payers use narrower language that effectively excludes stable disease.

Oncology: documenting continued benefit when the endpoint is control

What stable disease means in oncology

In oncology, stable disease (SD) is a formal RECIST 1.1 category. It means the sum of target lesion diameters has neither increased by 20% (progressive disease) nor decreased by 30% (partial response). For many advanced cancers, SD at 6 or 12 months is a clinically meaningful outcome that correlates with survival benefit.

Payer expectations for oncology renewal

Oncology PA renewal typically requires:

1. Imaging evidence showing no new lesions and no progression of existing disease
2. Tolerance documentation confirming the patient is tolerating therapy without dose-limiting toxicity
3. Functional status (ECOG or Karnofsky) demonstrating maintained or improved performance status
4. Tumor marker trends (if applicable) showing stability or improvement

A 2026 analysis from Droidal on oncology PA denials found that the most common reason for renewal denial is "missing required clinical documentation, such as diagnosis, treatment history, lab values, or imaging results." The denial is often not about whether the drug is working but whether the documentation proves it.

Documentation package for oncology reauthorization

For a patient with stable disease on an ongoing oncology regimen, the renewal package should include:

1. Comparison imaging report: The most recent scan with explicit comparison to the prior scan, using RECIST language ("stable disease per RECIST 1.1 criteria—sum of target lesion diameters changed by X% from baseline")
2. Radiology narrative: A brief note from the radiologist or treating oncologist stating "no evidence of disease progression" and "no new metastatic lesions identified"
3. Performance status: Current ECOG score documented within 30 days of the renewal submission
4. Treatment tolerance: Documentation that the patient is receiving the drug at the labeled dose and schedule without dose reductions or treatment delays due to toxicity
5. Clinical narrative: A statement from the oncologist explaining why continued treatment is appropriate—referencing pivotal trial data showing survival benefit with continued therapy beyond initial response assessment

Key oncology renewal scenarios

Immunology: documenting continued benefit when the endpoint is disease control

The DAS28, PASI, and Mayo score problem

Immunology reauthorization typically requires a disease activity score at renewal. But payers vary in what they consider sufficient:

• Rheumatoid arthritis: Some payers require DAS28 remission (<2.6) or low disease activity (<3.2); others accept moderate disease activity if improvement from baseline is documented
• Psoriasis: Some payers require PASI 75 (75% improvement); others accept PASI 50 with quality-of-life improvement
• Inflammatory bowel disease: Some payers require endoscopic remission; others accept clinical remission (Mayo score ≤2) or even symptomatic improvement with biomarker normalization

UnitedHealthcare's January 2026 medical policy update for Gazyva (obinutuzumab) in lupus nephritis illustrates the standard: continuation requires "documentation of positive clinical response" and authorization is limited to 12 months. The policy does not define "positive clinical response"—leaving the documentation burden on the prescriber.

Documentation package for immunology reauthorization

1. Current disease activity score: Measured within 30 days of renewal, using the same tool as the initial PA (DAS28-CRP, PASI, Mayo score, CDAI, etc.)
2. Comparison to baseline: The initial score documented in the original PA submission, with the current score showing stability or improvement
3. Corticosteroid taper documentation: If the patient has reduced steroid use while on the biologic, this is strong evidence of continued benefit
4. Flare history: Documentation of any flares, their severity, and how they were managed—demonstrating that the drug is preventing disease exacerbation
5. Quality-of-life measures: Patient-reported outcomes (HAQ-DI, DLQI, IBD-Q) showing maintained or improved function
6. Prescriber narrative: A statement from the rheumatologist, gastroenterologist, or dermatologist explaining why switching therapies would be inappropriate for this patient

The medication-switch risk

If reauthorization is denied, the payer may require a switch to a different drug—often a formulary-preferred agent. The Coalition of State Rheumatology Organizations (CSRO) has formally raised concerns with payers including Cigna and CVS Health about "unjustified downcoding and excessive administrative burden" that disrupts stable patients. The ACR's research has found that switching anti-TNF biologics in patients with persistent RA symptoms can produce improvements—but the opposite can also occur, and the disruption of a stable regimen carries clinical risk.

Manufacturer hub teams should anticipate this scenario and include in the renewal package a statement addressing why the current therapy should be continued rather than switched.

Rare disease: documenting continued benefit when the endpoint is stabilization

The unique challenge of rare disease reauthorization

Rare disease therapies face the hardest renewal standard because the evidence base is thinner, the patient population is smaller, and the disease trajectory often involves stabilization rather than improvement. Many rare disease drugs were approved based on surrogate endpoints or small single-arm trials, and payer policies may not reflect the clinical reality of managing a progressive rare disease.

Superior Health Plan's June 2026 PA criteria for palovarotene (Sohonos) in fibrodysplasia ossificans progressiva (FOP) illustrates the standard: continued therapy requires "documentation is provided that the member has achieved a clinical benefit from medication." For a disease measured by heterotopic ossification volume on whole-body CT scans, "benefit" may mean "no new HO formation"—which is stability, not improvement.

Documentation package for rare disease reauthorization

1. Baseline comparison: The pre-treatment baseline assessment (imaging, functional measure, biomarker) that was documented in the initial PA
2. Stability documentation: Explicit statement that the disease has not progressed since treatment initiation, with supporting data
3. Functional measures: Any validated functional assessment relevant to the disease (6-minute walk test, CAJIS score, pulmonary function tests)
4. Literature support: If the payer's clinical policy does not address the specific rare disease indication, include peer-reviewed literature demonstrating that stabilization is a clinically meaningful endpoint
5. Prescriber attestation: A statement from the treating specialist explaining that disease stabilization is the expected and appropriate treatment goal

Operational workflow to prevent treatment gaps

Start the renewal clock at authorization, not at the patient's appointment

The most common operational failure is waiting until the patient's next appointment to submit the renewal. If the PA is approved for 6 months and the patient's next visit is at month 5.5, the practice has two weeks to gather documentation, submit the PA, and receive a decision before the authorization lapses.

Recommended timeline:

Build indication-specific renewal templates

Manufacturer hub teams should create renewal documentation templates for each approved indication of their product. Each template should:

1. List the specific payer criteria for reauthorization (pulled from current payer policies)
2. Include the required disease activity tools and their thresholds
3. Provide a clinical narrative template that the prescriber can customize
4. Include a checklist of required supporting documents

Track authorization expiry dates

Specialty pharmacies and hub teams should maintain a renewal calendar with:

• Authorization expiry dates for every active patient
• The payer's required documentation for renewal
• The renewal submission deadline (typically 2–4 weeks before expiry)
• Escalation contacts for each payer

Evernorth/Accredo reports that 70% of specialty providers use its MAP platform, which provides visibility into PA expiration dates and notifications when PAs expire. Manufacturer hubs should build similar tracking capability.

Prepare for peer-to-peer review

When a renewal is denied, the fastest path to reversal is usually a peer-to-peer review with the payer's medical director. The prescriber should be prepared to:

1. Walk through the comparison data (baseline vs. current)
2. Explain why stability constitutes continued benefit for this patient
3. Reference the pivotal trial data supporting continued treatment
4. Cite any relevant compendia or guideline recommendations
5. Address the payer's specific denial reason directly

What the CMS proposed rule may change

The CMS proposed rule CMS-0062-P (April 2026) would require electronic PA for drugs starting October 1, 2027. For reauthorization workflows, the rule's most relevant provisions are:

• FHIR-based PA renewal: The Da Vinci PAS Implementation Guide supports PA renewal requests with updated clinical documentation, which could streamline the renewal process
• Specific denial reasons: Payers would be required to provide a specific reason for denying any drug PA request, including renewals—reducing the frequency of vague "insufficient documentation" denials
• 24-hour decision timeframe for outpatient drugs: Faster decisions reduce the risk of treatment gaps during renewal

Until these provisions take effect, the manual documentation workflow described above remains the standard.

What to monitor

• Payer reauthorization criteria updates: Policies are typically updated annually or semi-annually; verify current criteria before each renewal submission
• CMS-0062-P final rule: Electronic PA for drugs could streamline renewal workflows beginning October 2027
• State PA reform legislation: State laws increasingly address reauthorization timelines and criteria; several states now limit PA renewal frequency for chronic conditions
• Specialty pharmacy PA management platforms: Accredo MAP, CoverMyMeds, and similar platforms are building renewal tracking and electronic submission capabilities
• Biosimilar reauthorization: When a biosimilar enters the market, payers may change the preferred product at renewal, creating a forced-switch scenario that requires new documentation

This article is for informational purposes only and does not constitute medical advice, legal advice, or reimbursement guidance for any specific patient or plan. Coverage policies vary by payer, plan, and state. Always verify current payer criteria before submitting a reauthorization request.

Last updated: May 31, 2026.

Sources

• Alexion. "Guide to Reauthorization (Renewal of Authorization)." 2022. alexionaccessnavigator.com
• CoverMyMeds. "Common Denial Codes and Reasons for Oncology Prior Authorization." 2026. yonsarx.com
• Droidal. "What Causes Oncology Prior Authorization Denials and How AI Prevents Them." 2026. droidal.com
• Counterforce Health. "Specialty Drug Denials: The Complete Strategy for Appealing High Cost Medication Rejections in 2025." 2025. counterforcehealth.org
• UnitedHealthcare. "Commercial Medical Policy Update Bulletin." January 2026. uhcprovider.com
• Geisinger Health. "What's New: Medical Benefit Pharmacy Policy Updates." May 2026. geisinger.org
• Superior Health Plan. "Pharmacy and Biopharmacy Policies." Effective June 1, 2026. superiorhealthplan.com
• Minnesota SCHA. "Prior Authorization Criteria." Effective May 1, 2026. mnscha.org
• American Medical Association. "Combatting Misconceptions about Prior Authorization." 2024. ama-assn.org
• Evernorth/Accredo. "How Specialty Pharmacy Enhancements Help Physicians and Patients Navigate the Prior Authorization Process." August 2024. evernorth.com
• Coalition of State Rheumatology Organizations. "Federal Policy Correspondence." 2026. csro.info
• American College of Rheumatology. "The Rheum Advocate." May 21, 2026. rheumatology.org
• CMS. "2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P)." April 14, 2026. cms.gov